Hugues De Th

List of Publications by Year
in descending order

88 papers	12,363 citations	46744 46 h-index	44068 89 g-index
142 all docs	142 docs citations	142 times ranked	11071 citing authors

#	Article	IF	Citations
1	The PML-RARÎ± fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell, 1991, 66, 675-684.	27.7	1,366
2	The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor Î± gene to a novel transcribed locus. Nature, 1990, 347, 558-561.	35.8	1,309
3	Arsenic degrades PML or PMLâ€“RARÎ± through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nature Cell Biology, 2008, 10, 547-555.	9.9	651
4	All-trans retinoic acid/As ₂ O ₃ combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5328-5335.	7.5	568
5	PML Nuclear Bodies. Cold Spring Harbor Perspectives in Biology, 2010, 2, a000661-a000661.	5.3	492
6	Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor Î± Degradation. Journal of Experimental Medicine, 2001, 193, 1361-1372.	8.7	464
7	Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Reviews Cancer, 2010, 10, 775-783.	28.6	429
8	Differentiation therapy revisited. Nature Reviews Cancer, 2018, 18, 117-127.	28.6	340
9	Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine, 2008, 14, 1333-1342.	29.9	331
10	PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3. Cancer Cell, 2010, 18, 88-98.	16.6	306
11	Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia. Journal of Experimental Medicine, 1999, 189, 1043-1052.	8.7	304
12	Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene, 1999, 18, 935-941.	5.9	297
13	Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nature Medicine, 2008, 14, 617-621.	29.9	269
14	A pathway for phagosome maturation during engulfment of apoptotic cells. Nature Cell Biology, 2008, 10, 556-566.	9.9	247
15	Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer Cell, 2017, 32, 552-560.	16.6	231
16	PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers. Cell Metabolism, 2019, 29, 156-173.e10.	15.7	200
17	PML nuclear bodies: from architecture to function. Current Opinion in Cell Biology, 2018, 52, 154-161.	5.5	194
18	Oxidative stressâ€“induced assembly of PML nuclear bodies controls sumoylation of partner proteins. Journal of Cell Biology, 2014, 204, 931-945.	5.1	189

#	Article	IF	Citations
19	Acute promyelocytic leukemia, arsenic, and PML bodies. Journal of Cell Biology, 2012, 198, 11-21.	5.1	179
20	From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011, 117, 6425-6437.	1.4	173
21	Activation of a promyelocytic leukemiaâ€“tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nature Medicine, 2014, 20, 167-174.	29.9	168
22	Transcriptional regulation in acute promyelocytic leukemia. Oncogene, 2001, 20, 7204-7215.	5.9	153
23	PMLâ€“RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation. Journal of Experimental Medicine, 2004, 199, 1163-1174.	8.7	150
24	Pathways of retinoic acid- or arsenic trioxide-induced PML/RARÎ± catabolism, role of oncogene degradation in disease remission. Oncogene, 2001, 20, 7257-7265.	5.9	144
25	A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell, 2005, 7, 143-153.	16.6	142
26	Curing APL through PML/RARA degradation by As2O3. Trends in Molecular Medicine, 2012, 18, 36-42.	7.0	128
27	Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood, 2011, 117, 5795-5802.	1.4	112
28	Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood, 2015, 125, 3447-3454.	1.4	105
29	RXR Is an Essential Component of the Oncogenic PML/RARA Complex In Vivo. Cancer Cell, 2007, 12, 23-35.	16.6	104
30	Resistance to Therapy in Acute Promyelocytic Leukemia. New England Journal of Medicine, 2014, 371, 1170-1172.	29.7	102
31	Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARÎ± fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene, 1999, 18, 1113-1118.	5.9	97
32	PML is a ROS sensor activating p53 upon oxidative stress. Journal of Experimental Medicine, 2017, 214, 3197-3206.	8.7	83
33	Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. Journal of Experimental Medicine, 2013, 210, 647-653.	8.7	76
34	PML nuclear bodies: Assembly and oxidative stress-sensitive sumoylation. Nucleus, 2014, 5, 499-507.	2.2	76
35	PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14278-14283.	7.5	70
36	Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia. International Journal of Cancer, 2014, 135, 2262-2272.	5.4	69

#	Article	IF	Citations
37	Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Molecular Medicine, 2020, 12, e11622.	6.8	69
38	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. Cell Stem Cell, 2019, 25, 258-272.e9.	10.7	68
39	RING tetramerization is required for nuclear body biogenesis and PML sumoylation. Nature Communications, 2018, 9, 1277.	13.0	66
40	RARÎ±-PLZF overcomes PLZF-mediated repression of CRABPI , contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18694-18699.	7.5	63
41	Cytokinetic nodes in fission yeast arise from two distinct types of nodes that merge during interphase. Journal of Cell Biology, 2014, 204, 977-988.	5.1	61
42	ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. Blood, 2015, 125, 474-482.	1.4	61
43	Control of vertebrate intraflagellar transport by the planar cell polarity effector Fuz. Journal of Cell Biology, 2012, 198, 37-45.	5.1	59
44	Statistical properties of supersonic turbulence in the Lagrangian and Eulerian frameworks. Journal of Fluid Mechanics, 2012, 692, 183-206.	3.5	51
45	Interferon controls SUMO availability via the Lin28 and let-7 axis to impede virus replication. Nature Communications, 2014, 5, 4187.	13.0	47
46	The Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?. Cancer Discovery, 2011, 1, 117-127.	14.1	45
47	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. Cancer Discovery, 2021, 11, 3198-3213.	14.1	43
48	DNA methyltransferase 1 functions through C/ebpa to maintain hematopoietic stem and progenitor cells in zebrafish. Journal of Hematology and Oncology, 2015, 8, 15.	17.5	41
49	FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias. Blood, 2019, 133, 1495-1506.	1.4	39
50	Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Blood, 2014, 124, 3772-3780.	1.4	38
51	Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nature Communications, 2018, 9, 2047.	13.0	37
52	Classic and Variants APLs, as Viewed from a Therapy Response. Cancers, 2020, 12, 967.	3.8	36
53	Sumoylation in Physiology, Pathology and Therapy. Cells, 2022, 11, 814.	4.2	32
54	First principles assessment of helium trapping in Y2TiO5 in nano-featured ferritic alloys. Journal of Applied Physics, 2014, 116, .	2.3	30

#	Article	IF	Citations
55	Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation. Cancer Discovery, 2018, 8, 1614-1631.	14.1	30
56	Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia, 2022, 36, 1585-1595.	7.4	30
57	TAMM41 is required for heart valve differentiation via regulation of PINK-PARK2 dependent mitophagy. Cell Death and Differentiation, 2019, 26, 2430-2446.	11.3	26
58	Retinoids in hematology: a timely revival?. Blood, 2021, 137, 2429-2437.	1.4	26
59	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. Leukemia, 2021, 35, 2552-2562.	7.4	25
60	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. Journal of Experimental Medicine, 2021, 218, .	8.7	24
61	Promyelocytic Leukemia Protein (PML) ControlsListeria monocytogenesInfection. MBio, 2017, 8, .	4.3	23
62	PML nuclear bodies, membrane-less domains acting as ROS sensors?. Seminars in Cell and Developmental Biology, 2018, 80, 29-34.	5.3	18
63	Sumoylation of CCAAT/enhancer-binding protein Î± is implicated in hematopoietic stem/progenitor cell development through regulating runx1 in zebrafish. Scientific Reports, 2015, 5, 9011.	3.4	17
64	Facile one-pot synthesis, antibacterial activity and in silico ADME prediction of 1-substituted-1 H -1,2,3,4-tetrazoles. Chemical Data Collections, 2018, 15-16, 107-114.	2.3	14
65	GATA5 SUMOylation is indispensable for zebrafish cardiac development. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1691-1701.	2.4	13
66	A Pin1/PML/P53 axis activated by retinoic acid in <i>NPM-1c</i> acute myeloid leukemia. Haematologica, 2021, 106, 3090-3099.	3.4	13
67	A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells. Life Science Alliance, 2019, 2, e201800213.	2.9	13
68	CCAAT/enhancer-binding protein Î± is required for hepatic outgrowth via the p53 pathway in zebrafish. Scientific Reports, 2015, 5, 15838.	3.4	12
69	Yolk sac-derived Pdcd11-positive cells modulate zebrafish microglia differentiation through the NF-Î²B-Tgfî²1 pathway. Cell Death and Differentiation, 2021, 28, 170-183.	11.3	11
70	Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells. Nature Communications, 2022, 13, .	13.0	11
71	Interferon regulatory factor 2 binding protein 2b regulates neutrophil versus macrophage fate during zebrafish definitive myelopoiesis. Haematologica, 2020, 105, 325-337.	3.4	10
72	A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA. Leukemia, 2021, 35, 2784-2798.	7.4	8

#	Article	IF	Citations
73	Lessons taught by acute promyelocytic leukemia cure. Lancet, The, 2015, 386, 247-248.	12.1	7
74	Primitive macrophages are dispensable for HSPC mobilization and definitive hematopoiesis. Blood, 2019, 134, 782-784.	1.4	7
75	PML/RARa Destabilization by Hyperthermia: A New Model for Oncogenic Fusion Protein Degradation?. Blood Cancer Discovery, 2021, 2, 300-301.	5.7	7
76	Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function. Cancer Discovery, 2023, 13, 2548-2565.	14.1	7
77	Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Biomedicines, 2021, 9, 1704.	3.3	6
78	RNF4 regulates zebrafish granulopoiesis through the DNMT1â€C/EBPÎ± axis. FASEB Journal, 2018, 32, 4930-4940.	0.4	5
79	Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication. Leukemia, 2022, 36, 1306-1312.	7.4	5
80	The DNA Binding Property of PML/RARA but Not the Integrity of PML Nuclear Bodies Is Indispensable for Leukemic Transformation. PLoS ONE, 2014, 9, e104906.	2.5	4
81	New genetic tools in the diagnosis of growth defects. Growth Hormone and IGF Research, 2018, 38, 24-28.	1.2	4
82	A novel process for oxygen absorption from air using hollow fiber gas-liquid membrane contactor. Separation and Purification Technology, 2018, 193, 283-288.	8.0	4
83	The PML hub: An emerging actor of leukemia therapies. Journal of Experimental Medicine, 2023, 220, .	8.7	4
84	An exciting RXRA mutant revives interest in retinoids for acute myeloid leukemia. Haematologica, 2022, 107, 354-355.	3.4	1
85	History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies. Cancers, 2024, 16, 1351.	3.8	1
86	In APL, noncoding mutations and SNP converge on WT1. Blood, 2022, 140, 1060-1061.	1.4	0
87	Znf687 recruits Brd4-Smrt complex to regulate gfi1aa during neutrophil development. Leukemia, 2024, 38, 851-864.	7.4	0
88	Tripartite RAR fusions explain RA resistance. Blood, 2024, 144, 1461-1462.	1.4	0